PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease

International Journal of Cancer

Volumn 130, Issue 10, 2012, Pages 2327-2336

  Krönig, Holger ^a   Julia Falchner, Kathrin ^a   Odendahl, Marcus ^a,b   Brackertz, Bettina ^a   Conrad, Heinke ^a,c   Muck, Dieter ^a   Hein, Rüdiger ^a   Blank, Christian ^d   Peschel, Christian ^a   Haller, Bernhard ^a   Schulz, Stephan ^a   Bernhard, Helga ^a,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e KLINIKUM DARMSTADT   (Germany)

Author keywords

A2 Melan A; B7 H1; malignant melanoma; PD 1; PD L1

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; EPITOPE; FORMALDEHYDE; HLA A2 ANTIGEN; MELAN A; PARAFFIN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER TISSUE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISTANT METASTASIS; EFFECTOR CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; MEMORY T LYMPHOCYTE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE FIXATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

AGED; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84859104688     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26272     Document Type: Article

References (52)

1. Gajewski TF,. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006; 12: 2326s-2330s.
2. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF,. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64: 1140-5. (Pubitemid 38176921)
3. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N,. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-7.
4. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A,. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006; 119: 317-27.
5. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
6. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ,. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-45. (Pubitemid 46745373)
7. Dong H, Zhu G, Tamada K, Chen L,. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-9.
8. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-8. (Pubitemid 33706004)
9. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM,. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207: 2175-86.
10. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R,. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-7. (Pubitemid 43237609)
11. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-4. (Pubitemid 44435155)
12. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR,. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 2007; 81: 9249-58. (Pubitemid 47311467)
13. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z,. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 963-70. (Pubitemid 350019503)
14. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-202. (Pubitemid 44527357)
15. Wherry EJ, Ahmed R,. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78: 5535-45. (Pubitemid 38661640)
16. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
17. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006; 8: 190-8. (Pubitemid 43671234)
18. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S,. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 3360-5. (Pubitemid 46364164)
19. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101: 17174-9. (Pubitemid 39627793)
20. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF,. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114: 1528-36.
21. Keir ME, Butte MJ, Freeman GJ, Sharpe AH,. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704. (Pubitemid 351600389)
22. Blank C, Gajewski TF, Mackensen A,. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 307-14. (Pubitemid 40238924)
23. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED,. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005; 104: 2084-91. (Pubitemid 41579953)
24. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM,. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009; 182: 5240-9.
25. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y,. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116: 1757-66.
26. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P,. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160: 1750-8. (Pubitemid 28110836)
27. Fleischer K, Schmidt B, Kastenmuller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C, Bernhard H,. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. J Immunol 2004; 172: 162-9. (Pubitemid 38020468)
28. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH,. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8: 631-7. (Pubitemid 34633443)
29. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T,. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 1998; 75: 451-8. (Pubitemid 28100050)
30. Noether GE,. Sample size determination for some common nonparametric tests. JASA 1987; 82: 645-7.
31. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
32. SPSS. PASW Statistics, Rel. 17.0.2. Chicago: SPSS Inc., 2009. Available at
33. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48. (Pubitemid 32786276)
34. D'souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P,. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer 1998; 78: 699-706. (Pubitemid 28530392)
35. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA,. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 1996; 19: 266-77. (Pubitemid 26313518)
36. Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L,. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996; 184: 647-57. (Pubitemid 26324118)
37. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G,. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999; 190: 651-67. (Pubitemid 29429007)
38. Griffioen M, Borghi M, Schrier PI, Osanto S,. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-γ-ELISPOT assay. Int J Cancer 2001; 93: 549-55. (Pubitemid 32701414)
39. Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P,. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-γ ELISPOT assays for patient immune monitoring. J Immunother 2004; 27: 298-308. (Pubitemid 38833326)
40. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF,. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006; 55: 1185-97. (Pubitemid 43992045)
41. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 6169-76. (Pubitemid 41508105)
42. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004; 64: 2865-73. (Pubitemid 38500627)
43. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M,. Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res 2007; 141: 72-7. (Pubitemid 46898447)
44. Ilkovitch D, Lopez DM,. Immune modulation by melanoma-derived factors. Exp Dermatol 2008; 17: 977-85.
45. Mourmouras V, Fimiani M, Rubegni P, Epistolato MC, Malagnino V, Cardone C, Cosci E, Nisi MC, Miracco C,. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br J Dermatol 2007; 157: 531-9. (Pubitemid 47256132)
46. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H,. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992; 175: 139-46.
47. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA,. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-44.
48. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C,. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117: 2192-201.
49. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH,. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-29.
50. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI,. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-802.
51. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ, van der Burg SH,. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009; 15: 6341-7.
52. Disis ML, Bernhard H, Jaffee EM,. Use of tumour-responsive T cells as cancer treatment. Lancet 2009; 373: 673-83.